SCHEMBL2284366

SCHEMBL2284366

Cc1cc(O)c(C(=O)C=Cc2cccc(N)c2)c(=O)n1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.48
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 1/20 0.46
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
SLC5A1 P13866 2/20 0.43
SLC5A2 P31639 2/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
ABCB1 P08183 3/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284361 1.00 NPSR1 (0.48) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL15233123 0.88 MAOA (0.49) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2281390 0.88 MAOA (0.51) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2281391 0.88 MAOA (0.51) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2285404 0.85 P4HB (0.53) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2285409 0.85 P4HB (0.53) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2278721 0.84 TTR (0.47) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2278723 0.84 TTR (0.47) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2279947 0.83 NPC1 (0.42) NPSR1NPC1RAB9AKMT2AUSP2
SCHEMBL2279945 0.83 NPC1 (0.42) NPSR1NPC1RAB9AKMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 NPSR1 3209/4885NPC1 1610/4885RAB9A 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.